Ignite Creation Date:
2024-05-05 @ 9:11 PM
Last Modification Date:
2024-10-26 @ 10:01 AM
Study NCT ID:
NCT00836927
Status:
TERMINATED
Last Update Posted:
2019-02-18
First Post:
2009-02-03
Brief Title:
Extension Trial of Deforolimus Ridaforolimus MK-8669 in Participants With Advanced Cancer MK-8669-038
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
An Extension Trial of Deforolimus AP23573 MK-8669 an mTOR Inhibitor for Patients With Advanced Cancer
Status:
TERMINATED
Status Verified Date:
2019-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To describe the long-term safety of deforolimus ridaforolimus MK-8669 in participants for whom a clinical benefit has been established in a prior parent trial MK-8669-013 NCT00060645 MK-8669-016 NCT00112372 and MK-8669-028 NCT00704054 with deforolimus andor in those who remain in long-term follow-up
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AP23573-08-901 | OTHER | None | None |
| MK-8669-038 | OTHER | Merck Protocol Number | None |